Vitrasert for cytomegalovirus (CMV) retinitis

The FDA just approved Vitrasert for cytomegalovirus (CMV) retinitis. Vitrasert is implanted surgically in the eye. It releases the antiviral ganciclovir for about six months.

The implant works better than IV ganciclovir...probably because it achieves higher drug levels in the eye.

Vitrasert DOESN'T prevent CMV infections in the other eye or elsewhere in the body. Expect to see some patients get combo therapy with Vitrasert AND systemic ganciclovir (Cytovene).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote